CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes

Phase 1Biologic

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes is one of 27 biologic programs targeting B Acute Lymphoblastic Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

B Acute Lymphoblastic LeukemiaActive, not recruiting

B Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

26 competitors in B Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

5 2

Trexall

Jazz Pharmaceuticals

Phase 3

5 3

Oncovin

Eli Lilly

Phase 3

3 4

Blincyto

Amgen

Phase 3

3 5

Adriamycin

Pfizer

Phase 3

3 6

Adriamycin

Pfizer

Phase 3

2 7

Rituxan

Roche

Phase 3

2 8

Zyloprim

Jazz Pharmaceuticals

Phase 3

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

7 10

Purinethol

SStason

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

B Acute Lymphoblastic Leukemia

NCT02146924

Clinical

Trials by Indication[1]

B Acute Lymphoblastic Leukemia1 trial

Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With High-Risk CD19+ Acute Lymphoblastic Leukemia

Active, not recruiting·CCity of Hope Medical Center·Phase 1·NCT02146924·71 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — City of Hope Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCity of Hope Medical Center

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

B Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News